Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

Amgen announced that its drug, when combined with AstraZeneca's immunotherapy, reduced the risk of death by 58 percent in patients with a specific form of lung cancer. The company did not specify the drug name, patient sample size, or the stage of clinical testing in the available statement. Amgen said it plans to present detailed trial results at a medical conference.

• CNBC — Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

Next story